Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-14
2009-08-11
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000
Reexamination Certificate
active
07572771
ABSTRACT:
Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.
REFERENCES:
patent: 4643988 (1987-02-01), Segrest et al.
patent: 5733879 (1998-03-01), Rosseneu et al.
patent: 6046166 (2000-04-01), Dasseux et al.
patent: 6156727 (2000-12-01), Garber et al.
patent: 6376464 (2002-04-01), Dasseux et al.
patent: 6518412 (2003-02-01), Dasseux et al.
patent: 6573239 (2003-06-01), Dasseux et al.
patent: 6602854 (2003-08-01), Dasseux et al.
patent: 6630450 (2003-10-01), Dasseux et al.
patent: 2003/0022901 (2003-01-01), Childrens et al.
patent: 2003/0191057 (2003-10-01), Fogelman et al.
Segrest et al., J. Lipid Res. 33: 141-166, 1992.
Bolanos-Garcia and Nunez, “On the structure and function of apolipoproteins: more than a family of lipid-binding proteins,”Progress in Biophysics and Molecular Biology, 83(1):47-68, 2003.
Brewer, “High-Density Lipoproteins: A New Potential Therapeutic Target for the Prevention of Cardiovascular Disease,”Arterioscler. Thromb. Vasc. Biol., 24:387-391, 2004.
Datta, et al., “Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide,”Journal of Lipid Research, 42:1096-1104, 2001.
Eisenberg et al., “Hydrophobic Moments and Protein Structure,”Faraday Symp. Chem. Soc., 17:109-120, 1982.
Eisenberg et al., “Analysis of membrane and surface protein sequences with the hydrophobic moment plot,”J. Mol. Biol., 179(1):125-142, 1984.
Eisenberg et al., “The hydrophobic moment detects periodicity in protein hydrophobicity,”Proc. Natl. Acad. Sci. U.S.A., 81(1):140-144, 1984.
Fitzgerald et al., “Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I,”J. Biol. Chem., 277(36):33178-33187, 2002.
Garber et al., “A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis,”Journal of Lipid Research, 42:545-552, 2001.
Kanellis et al., “Studies of Synthetic Peptide Analogs of the Amphipathic Helix,”J. Biol. Chem., 255:11464-11472, 1980.
Kyte and Doolittle, “A simple method for displaying the hydropathic character of a protein,”J. Mol. Biol., 157:105-132, 1982.
Labeur et al., “Design of a New Class of Amphipathic Helical Peptides for the Plasma Apolipoproteins That Promote Cellular Cholesterol Efflux But Do Not Activate LCAT,”Arterioscler. Thromb. Vasc. Biol., 17:580-588, 1997.
Mendez et al., “Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol,”J. Clin. Invest., 94(4):1698-1705, 1994.
Mishra et al., “Effect of the Arrangement of Tandem Repeating Units of Class A Amphipathic α-Helixes on Lipid Interaction,”J. Biol. Chem., 270(4):1602-1611, 1995.
Mishra et al., “Studies of Synthetic Peptides of Human Apolipoprotein A-I Containing Tandem Amphipathic α-Helixes,”Biochem., 37:10313-10324, 1998.
Nissen et al., “Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes,”JAMA, 290(17):2292-2300, 2003.
Panagotopulos et al., “The Role of Apolipoprotein A-I Helix 10 in Apolipoprotein-mediated Cholesterol Efflux via the ATP-binding Cassette Transporter,”J. Biol. Chem., 277(42):39477-39484, 2002.
Remaley et al., “Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway,”J. Lipid Res., 44(4):828-836, 2003.
Rubin et al., “Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI”Nature, 353:265-267, 1991.
Tossi et al., “New consensus hydrophobicity scale extended to non-proteinogenic amino acids,”Peptides, Ettore Benedetti and Carlo Pedone (Eds.), Napoli, Italy, 2002, 2 pages.
Wang et al., “The helix-hinge-helix structural motif in human apolipoprotein A-I determined by NMR spectroscopy,”Biochem., 36(44):13657-13666, 1997.
Amar Marcele J. A.
Brewer H. Bryan
Demosky Stephen J.
Neufeld Edward B.
Remaley Alan T.
Chandra Gyan
Klarquist Sparkman LLC
Landsman Robert
The United States of America as represented by the Departments o
LandOfFree
Multi-domain amphipathic helical peptides and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multi-domain amphipathic helical peptides and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multi-domain amphipathic helical peptides and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4108820